GSK presents positive data at ATS 2014 from study evaluating efficacy and safety of Incruse™ Ellipta® added to Advair® Diskus® in patients with COPD

In this study the safety and efficacy of the addition of a long-acting muscarinic antagonist (also known as an anticholinergic), umeclidinium ‘UMEC’ 62.5mcg (IncruseTM Ellipta®) and UMEC 125mcg, to the inhaled corticosteroid and long-acting beta2 agonist combination medicine, fluticasone proprionate and salmeterol ‘FSC 250/50 mcg’ (Advair ® Diskus®), was evaluated in chronic obstructive pulmonary disease (COPD) patients over 12 weeks.
Source: GSK news - Category: Pharmaceuticals Source Type: news